

Time Table
Day 2, July 20 (Fri)

			7	8	9	10	11	12	13	14	15	16	17	18	19	
Kobe International Exhibition Hall	Kobe Portopia Hotel	Room 1 (Portopia Hall)	South Building 1F			ISY4 Molecular diagnosis for treatment of colorectal cancer <small>E 8:30-10:00</small>				PS Plenary Session <small>13:15-14:45</small>	SY10 Future prospects of genome-based medicine in Japan <small>14:50-16:50</small>					
		Room 2 (Convention Hall South)	Hall No.2 1F	MoS-13 Clinical Validation of Guardant360 and Current clinical utility of liquid biopsy. <small>7:30-8:20</small>	SY11 Liquid Biopsy <small>E 8:30-10:30</small>		General Assembly	Award Lecture	MeS-14 ~Aiming for Cure- Future prospects of treatment strategy for the patients with unresectable Stage III NSCLC patients <small>12:10-13:00</small>			SY12 Current strategy for EGFR mutant NSCLC <small>14:50-16:50</small>				
		Room 3 (Hall A)	Hall No.1 2F		EL11 Presentation at the international meeting <small>8:30-9:00</small>	EL12 On writing well <small>9:00-9:30</small>	EL13 Current status of fertility preservation as a cancer survivorship in Japan <small>8:30-10:00</small>	EL14 Communication skill with the Myers-Briggs Type Indicator (MBTI®) <small>10:00-10:30</small>		MeS-15 Treatment strategy for lung cancer in the era of upfront new combination therapy -ICI, TKI and cytotoxic chemotherapy and their combinations <small>12:10-13:00</small>		EL15 Principles of cancer immunotherapy <small>14:50-15:20</small>	EL16 免疫療法の新展開 <small>15:20-15:50</small>	O2-1 Immunotherapy 4 (Melanoma/Others) <small>15:50-16:50</small>	ES-12 The importance of optimal drug sequencing in mCRC: biological rationales for the patients benefit and future perspective <small>17:10-18:00</small>	
		Room 4 (Hall B)	Hall No.1 2F	MoS-1 Points to note in genetic testing by Next Generation Sequencing for NSCLC in clinical practice and CP4AF-V500C mutation as therapeutic target. <small>7:30-8:20</small>	JS4 Joint Symposium 4 (JCS/JSMO) Learning onco-cardiology from case study <small>8:30-10:30</small>				MeS-16 Gastric Cancer <small>12:10-13:00</small>			SY13 Angiogenesis inhibitor for gastrointestinal tumors <small>14:50-16:50</small>			ES-13 The importance of optimal drug sequencing in mCRC: biological rationales for the patients benefit and future perspective <small>17:10-18:00</small>	
		Room 5 (Conference Room 2A)	Hall No.2 2F		ISY5 Immunotherapies for Head and Neck Cancer <small>E 8:30-10:30</small>				MeS-17 The current status and future direction of new drug development for mCRC <small>12:10-13:00</small>			SY14 The sequential therapy for urological cancer <small>14:50-16:20</small>			ES-14 For the Management of Skin Toxicity Associated with Immune Checkpoint Inhibitors and concomitant drugs: A feedback from the Consensus meeting 2018 with Volunteer Medical Oncologists and Dermatologists <small>17:10-18:40</small>	
		Room 14 (Conference Room 2B)	Hall No.2 2F	MoS-2 Impact of TKIs on primary organs -Cardio-Renal Association for oncologists- <small>7:30-8:20</small>					MeS-18 Is Immuno-check point inhibitor the Breakthrough for Urothelial Cancer? <small>12:10-13:00</small>						ES-15 How to decipher New Gastric Cancer Treatment Guidelines: From major to minor changes <small>17:10-18:00</small>	
		Room 6 (Conference Room 3A)	Hall No.2 3F		SY15 Evolution of therapeutic concepts for hematologic malignancies <small>8:30-10:30</small>				MeS-19 chemotherapy management of malignant lymphoma ~a pharmacist's viewpoint~ ~a nurse's viewpoint~ <small>12:10-13:00</small>			SY16 Dose-dense TC vs TC+BEV as primary chemotherapy for ovarian cancer <small>14:50-16:20</small>	EL17 Medical and psychosocial considerations in healthy cancer syndromes which oncologists of NSCLC should know <small>16:20-16:50</small>	ES-16 Treatment Strategy for Transplant Ineligible Newly Diagnosed Multiple Myeloma with Novel Agents <small>17:10-18:00</small>		
	Room 7 (Conference Room 3B)	Hall No.2 3F	MoS-3 Future perspectives of liquid biopsy for cancer precision medicine <small>7:30-8:20</small>	O2-2 Translational Research <small>8:30-9:30</small>	O2-3 Genitourinary Cancer <small>9:30-10:30</small>			MeS-20 Precision Medicine in the U.S.: Current Status and Future Perspective for Cancer Patients <small>12:10-13:00</small>			O2-4 Novel Treatment/Trials in Progress <small>14:50-15:50</small>	O2-5 Regulatory Science <small>15:50-16:50</small>	ES-17 Chemotherapy for Cervical Cancer ~Is CPT-11/NDP necessary?~ <small>17:10-18:00</small>			
Kobe Portopia Hotel		Room 8 (Kairaku)	Main Building B1F		SY17 Multidisciplinary care to assist cancer patients to keep working <small>8:30-10:30</small>			MeS-21 Immunotherapy of advanced NSCLC: from 2nd line to near future. <small>12:10-13:00</small>		PS Plenary Session (relay) <small>13:15-14:45</small>	SY18 Communication <small>14:50-16:20</small>			ES-18 The positioning of Immunecheckpoint inhibitor and biomarkers in NSCLC <small>17:10-18:40</small>		
		Room 9 (Kairaku)	Main Building B1F	MoS-4 New prospective of platinum sensitive recurrent ovarian cancer <small>7:30-8:20</small>	ISY6 Future Perspectives of PARP inhibitor <small>E 8:30-10:30</small>			MeS-22 Optimizing outcomes in HR+/HER2- mBC <small>12:10-13:00</small>				EJS ESMO/JSMO Joint Symposium Health economics and medical care <small>14:50-16:20</small>	ES-19 Current issues in outpatient chemotherapy <small>17:10-18:00</small>			
Kobe International Conference Center		Room 10 (Main Hall)	1F		SY19 Palliative Care Up-to-date <small>8:30-10:30</small>			MeS-23 New Strategy for Metastatic Colorectal Cancer ~Need to decide mCRC treatment according to patient's wishes~ <small>12:10-13:00</small>			SY20 Bridging cancer survivorship research and practice gap <small>13:30-16:30</small>					
		Room 11 (International Conference Room)	3F	MoS-5 Benefit and risk for nivolumab <small>7:30-8:20</small>	MP2 Automation of preparation of anticancer agents - current status and future prospects- <small>8:30-10:30</small>			MeS-24 Liquid Biopsy: Technologies and Clinical Applications <small>12:10-13:00</small>				SY21 New target therapies for soft tissue sarcoma <small>14:50-16:50</small>		ES-20 Treatment of Soft Tissue Sarcoma <small>17:10-18:00</small>		
		Room 12 (501)	5F	MoS-6 Multidisciplinary approach to soft tissue sarcoma -Benefits and case study- <small>7:30-8:20</small>	O2-6 Patient Advocacy/Cancer Survivorship <small>8:30-9:30</small>	O2-7 Esophageal Cancer <small>9:30-10:30</small>		MeS-25 Cancer immunotherapy ~Current status and Future perspective~ <small>12:10-13:00</small>				O2-8 Breast Cancer 1 (Systemic Therapy) <small>14:50-15:50</small>	O2-9 Breast Cancer 2 (Translational Research) <small>15:50-16:50</small>	ES-21 How can we apply The Japanese Breast Cancer Society Guideline 2018 to clinical practice? <small>17:10-18:00</small>		
		Room 13 (502)	5F	MoS-7 これからのER陽性乳癌の治療戦略 ~化学療法に求められる役割~ <small>7:30-8:20</small>	O2-10 Lung Cancer 5 (EGFR Mutation-positive NSCLC 1) <small>8:30-9:30</small>	O2-11 Lung Cancer 6 (EGFR Mutation-positive NSCLC 2) <small>9:30-10:30</small>		MeS-26 Perioperative chemotherapy for advanced gastric cancer: Asian Perspectives <small>12:10-13:00</small>				O2-12 Gastric Cancer 3 <small>14:50-15:50</small>	O2-13 Malignant Lymphoma 1 <small>15:50-16:50</small>	ES-22 The Latest Updates and Clinical Practice in ALK/ROS1-positive lung cancer <small>17:10-18:00</small>		
		Patient Advocate Program (401+402)	4F		PAP がん薬物療法のイロハ <small>9:30-10:20</small>	PAP がんの免疫療法 これまでとこれから <small>10:40-11:30</small>		PAP ランチョンセミナー: がんゲノム医療のこれから <small>12:10-13:00</small>				SY20 Bridging cancer survivorship research and practice gap (relay) <small>13:30-16:30</small>				
Kobe International Exhibition Hall	Poster Area (Convention Hall North)	Hall No.2 1F		8:00-9:00 Poster Set-up										9:00-18:10 Poster Display	18:10-19:00 Poster Session	19:00-19:30 Poster removal

Explanatory Notes

- JS =Joint Symposium
- EJS =ESMO/JSMO Joint Symposium
- ISY =International Symposium
- SY =Symposium
- PS =Plenary Session
- EL =Educational Lecture
- MoS =Morning Seminar
- MeS =Medical Seminar
- ES =Evening Seminar
- O =Oral
- P =Poster
- Simultaneous Interpretation (E&J)
- English Session
- Sponsored by Princess Takamatsu Cancer Research Fund